Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug shows promise in treating indolent non-Hodgkin lymphomas

23.01.2014
Idelalisib could be on the market later this year, pending FDA approval

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

But a new drug made by Seattle-based Gilead Sciences Inc. appears to offer hope for fighting the disease, according to a study published online today in the New England Journal of Medicine in advance of its March 13 print issue.

The phase 2 study involved 125 patients aged 33 to 87 with indolent non-Hodgkin lymphoma (iNHL) who had not responded to conventional treatments or had relapsed within six months of therapy. The patients, who were from the Seattle area, around the United States and Europe, were given a twice-daily dose of idelalisib, a highly selective oral drug that inhibits phosphoinositide 3-kinase (PI3K) delta. P13K deltas are a family of enzymes seen in many types of B-cell malignancies.

Following treatment with idelalisib, tumor size shrunk by at least half in 57 percent of the patients and 6 percent had no measurable evidence of cancer.

"These are patients who had exhausted current standard therapies," said Ajay Gopal, M.D., a member of Fred Hutchinson Cancer Research Center's Clinical Research Division and the study's lead and corresponding author. "In terms of effective therapy available, there really wasn't much left."

Indolent non-Hodgkin lymphomas comprise about one-third of all cases of NHL. About 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a combination of rituximab, a drug that targets the protein CD20 found on B cells, and chemotherapy.

While conventional treatment can be initially effective, iNHLs relapse over time and can lead to life-threatening complications such as infections and marrow failure. And unlike the toxic effects of chemotherapy, the most common side effects among patients in the trial were diarrhea and colitis, which occurred in a minority of participants and could usually be managed with dosage adjustments.

The NEJM paper, which was funded by Gilead Sciences and involved co-authors from 17 institutions in the U.S. and Europe, is the first publication of clinical data on idelalisib. The U.S. Food and Drug Administration (FDA) accepted the drug for review in early January and also gave it a Breakthrough Therapy designation for treatment of relapsed chronic lymphocytic leukemia (CLL) based on the results of another clinical trial.

Gopal, who helped write the protocol for the trial and treated many of the patients involved, said while it doesn't appear that the drug is curative, it holds tremendous promise for helping to control the disease for long periods of time.

"I think there's going to be a lot of interest in it," he said.

Gopal, also an associate professor at the University of Washington School of Medicine and the director of clinical research for hematology at Seattle Cancer Care Alliance, said depending on the FDA review, idelalisib could be approved for clinical use later this year. Such drugs, he said, represent a highly targeted and less harmful approach to treating cancer.

"Chemotherapy is a very blunt instrument," he said. "This is much more specific."

Deborah Bach | EurekAlert!
Further information:
http://www.fredhutch.org

More articles from Health and Medicine:

nachricht In Alzheimer's mice, memory restored with cancer drug
01.04.2015 | Yale University

nachricht New concept: Can Resuscitation be delayed?
31.03.2015 | Europäische Akademie Bozen - European Academy Bozen/Bolzano

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Lizard activity levels can help scientists predict environmental change

Research study provides new tools to assess warming temperatures

Spring is here and ectotherms, or animals dependent on external sources to raise their body temperature, are becoming more active. Recent studies have shown...

Im Focus: Hannover Messe 2015: Saving energy with smart façades

Glass-fronted office buildings are some of the biggest energy consumers, and regulating their temperature is a big job. Now a façade element developed by Fraunhofer researchers and designers for glass fronts is to reduce energy consumption by harnessing solar thermal energy. A demonstrator version will be on display at Hannover Messe.

In Germany, buildings account for almost 40 percent of all energy usage. Heating, cooling and ventilating homes, offices and public spaces is expensive – and...

Im Focus: Nonoxide ceramics open up new perspectives for the chemical and plant engineering

Outstanding chemical, thermal and tribological properties predestine silicon carbide for the production of ceramic components of high volume. A novel method now overcomes the procedural and technical limitations of conventional design methods for the production of components with large differences in wall thickness and demanding undercuts.

Extremely hard as diamond, shrinking-free manufacturing, resistance to chemicals, wear and temperatures up to 1300 °C: Silicon carbide (SiSiC) bundles all...

Im Focus: Experiment Provides the Best Look Yet at 'Warm Dense Matter' at Cores of Giant Planets

In an experiment at the Department of Energy's SLAC National Accelerator Laboratory, scientists precisely measured the temperature and structure of aluminum as...

Im Focus: Energy-autonomous and wireless monitoring protects marine gearboxes

The IPH presents a solution at HANNOVER MESSE 2015 to make ship traffic more reliable while decreasing the maintenance costs at the same time. In cooperation with project partners, the research institute from Hannover, Germany, has developed a sensor system which continuously monitors the condition of the marine gearbox, thus preventing breakdowns. Special feature: the monitoring system works wirelessly and energy-autonomously. The required electrical power is generated where it is needed – directly at the sensor.

As well as cars need to be certified regularly (in Germany by the TÜV – Technical Inspection Association), ships need to be inspected – if the powertrain stops...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Conference On Regenerative Medicine 2015: Registration And Abstract Submission Now Open

25.03.2015 | Event News

University presidents from all over the world meet in Hamburg

19.03.2015 | Event News

10. CeBiTec Symposium zum Big Data-Problem

17.03.2015 | Event News

 
Latest News

NASA covers Super Typhoon Maysak's rainfall, winds, clouds, eye

01.04.2015 | Earth Sciences

Quantum teleportation on a chip

01.04.2015 | Information Technology

Galaxy Clusters Formed as 'Fireworks'

01.04.2015 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>